CENTOGENE N.V.

CENTOGENE N.V. website preview
public biotech Rostock 3 sources
Own this company? Claim the page to unlock editing and verified-owner badge.

Centogene N.V. provides pharmaceutical solutions and diagnostic tests focusing on data-driven answers for rare and neurodegenerative diseases.

Classification

Rostock DE public biotech other b2b bioinformatics HealthBiotechGenetic Diagnostics

Profile

Founded
2008
Headcount
200+
Tech stack
PCR-free whole-genome sequencing, automated bioinformatics pipeline, AI-driven variant interpretation, cloud-computing (AWS)
Revenue range
€10-50M

Funding

Funding details not yet available.

Business model
💡 Value Proposition

Essential life science partner providing data-driven answers for rare and neurodegenerative diseases to patients, physicians, and pharmaceutical companies.

👥 Customer Segments

Pharmaceutical companies, physicians, and patients, with global reach across Europe, the Middle East, North America, Latin America, and Asia Pacific.

💰 Revenue Model

Revenue derived from providing pharmaceutical solutions and diagnostic tests to a global market of industry and clinical clients.

📡 Channels

Global distribution network operating across Europe, the Middle East, North America, Latin America, and the Asia Pacific.

🤝 Key Partnerships

Contract research organizations for clinical trials; healthcare providers and patient advocacy groups.

⚖️ Cost Structure

R&D, clinical trials, regulatory compliance, specialized manufacturing, and marketing.

🏗️ Key Resources

Proprietary data-driven platform and pharmaceutical/diagnostic solutions focused on rare and neurodegenerative diseases.

⚙️ Key Activities

Providing pharmaceutical solutions and diagnostic tests to deliver data-driven answers for rare and neurodegenerative disease contexts.

💬 Customer Relationships

High-touch account management for pharma and large hospital systems - dedicated liaisons, quarterly business reviews, and custom data-sharin · Self-service portal with AI-driven variant interpretation - empowers clinicians to explore results, request re-analysis, and access educatio · Patient support programs - multilingual helplines, counseling re

Strategic analysis
🏁 Competitive landscape

Competes with other biopharma companies specializing in orphan drugs and rare diseases (e.g., Biogen, Protalix). Differentiates through its specific focus on LSTs and advanced vector technologies.

🎯 Market pains

Need for data-driven answers and specialized pharmaceutical solutions for rare and neurodegenerative diseases for physicians and pharma.

💎 Improvement suggestions
  • Credibility
Investors

No investors recorded yet.

Sources & references

Web verified · 3 sources
Enriched 18 Jun 2026